Spike Protein Deletions Linked to COVID-19 Surges: Preprint
Spike Protein Deletions Linked to COVID-19 Surges: Preprint
Researchers find that surges in COVID-19 case numbers are associated with deletions in the SARS-CoV-2 genome in an antigenic site of the spike protein. Some of these mutations are present in vaccine breakthrough infections or reinfections.
Spike Protein Deletions Linked to COVID-19 Surges: Preprint
Spike Protein Deletions Linked to COVID-19 Surges: Preprint

Researchers find that surges in COVID-19 case numbers are associated with deletions in the SARS-CoV-2 genome in an antigenic site of the spike protein. Some of these mutations are present in vaccine breakthrough infections or reinfections.

Researchers find that surges in COVID-19 case numbers are associated with deletions in the SARS-CoV-2 genome in an antigenic site of the spike protein. Some of these mutations are present in vaccine breakthrough infections or reinfections.

spike protein
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Marcus A. Banks | Mar 1, 2021
A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.
First US Case of UK SARS-CoV-2 Variant Detected
First US Case of UK SARS-CoV-2 Variant Detected
Max Kozlov | Dec 30, 2020
Variant B.1.1.7, though likely more contagious than other strains, does not appear to be more deadly.
UPDATED DEC 21
New SARS-CoV-2 Variant Spreading Rapidly in UK
New SARS-CoV-2 Variant Spreading Rapidly in UK
Max Kozlov | Dec 16, 2020
The significance of the variant remains unclear, but experts remain confident that it will not evade the protection offered by a COVID-19 vaccine.
The Promise of mRNA Vaccines
The Promise of mRNA Vaccines
Diana Kwon | Nov 25, 2020
Long before Moderna’s and Pfizer’s COVID-19 shots, scientists had been considering the use of genetically encoded vaccines in the fight against infectious diseases, cancer, and more.
Immunity to SARS-CoV-2 Lasts at Least Six Months, Data Show
Immunity to SARS-CoV-2 Lasts at Least Six Months, Data Show
Ashley Yeager | Nov 23, 2020
Half a year after infection, people who had recovered from COVID-19 had robust antibodies, along with traces of the virus in their gut, which may drive long-lasting immunity.
Scientists Probe Blockers for the Coronavirus Spike Protein
Scientists Probe Blockers for the Coronavirus Spike Protein
Anthony King | Nov 5, 2020
SARS-CoV-2, the virus that causes COVID-19, taps into human proteases such as furin to enter cells. Temporarily inhibiting those enzymes might stymie infection.
SARS-CoV-2 Antibody Durability
SARS-CoV-2 Antibody Durability
The Scientist Creative Services Team | Oct 2, 2020
Experts will discuss their research on SARS-CoV-2 antibody persistence and immune memory in recovered COVID-19 patients and the implications for protective immunity.
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Anthony King | Sep 8, 2020
Adenovirus vectors deliver the genetic instructions for SARS-CoV-2 antigens directly into patients’ cells, provoking a robust immune response. But will pre-existing immunity from common colds take them down?
Modeling Study Flags Species Susceptible to SARS-CoV-2
Modeling Study Flags Species Susceptible to SARS-CoV-2
Anthony King | Aug 26, 2020
Some critically endangered animals are on the list.
Differences in Antibody Responses Linked to COVID-19 Outcomes
Differences in Antibody Responses Linked to COVID-19 Outcomes
Katarina Zimmer | Aug 18, 2020
In a small study of patients hospitalized due to SARS-CoV-2 infection, researchers report distinct early differences between the antibody responses of patients who recovered and those who died, possibly paving the way for a tool to predict disease prognosis.
First Antibody Trial Launched in COVID-19 Patients
First Antibody Trial Launched in COVID-19 Patients
Katarina Zimmer | Jun 2, 2020
In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.
COVID-19 Vaccine Researchers Mindful of Immune Enhancement
COVID-19 Vaccine Researchers Mindful of Immune Enhancement
Katarina Zimmer | May 26, 2020
There is no evidence that any of the coronavirus vaccines in development worsen a coronavirus infection rather than confer immunity to it, but the phenomenon is something scientists are closely monitoring.
Moderna’s Coronavirus Vaccine Spurs Immune Response: Early Data
Moderna’s Coronavirus Vaccine Spurs Immune Response: Early Data
Ashley Yeager | May 18, 2020
A clinical trial of the shot in eight volunteers suggests that it is safe and that it generates antibodies that neutralize SARS-CoV-2, but further testing is needed, scientists say.
Crowdsourced Protein Simulation Exceeds Supercomputers’ Power
Crowdsourced Protein Simulation Exceeds Supercomputers’ Power
Shawna Williams | Apr 15, 2020
Folding@Home, currently focused on deciphering the workings of SARS-CoV-2, is the first project to have exascale-level computational muscle.
Scientists Scan for Weaknesses in the SARS-CoV-2 Spike Protein
Scientists Scan for Weaknesses in the SARS-CoV-2 Spike Protein
Chris Baraniuk | Apr 9, 2020
The virus’s tool for prying open host cells is coated in a protective armor of sugar—but gaps may offer vulnerability to disruption by antibodies.
Novel Virus Entry Portal Found
Novel Virus Entry Portal Found
Sabrina Richards | Mar 13, 2013
Researchers identify the target protein of a recently discovered human coronavirus, shedding light on infection and possible interspecies spread.